Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

245 First Street, 18th Floor, Cambridge, United States

mdemattia May. 10 at 1:04 AM

$BDTX Lot of action in BDTX on Friday. My belief it is pre-ASOC accumulation . 🤞

2 · Reply

jimbecker May. 8 at 5:36 PM

$BDTX Starting small. In @ $3.02.

0 · Reply

Invest2live May. 8 at 3:40 PM

$RXT 1104% in 3 months; congrats 😊🌿🔆 Checkout $ARAY and $AKBA as well as $BDTX

0 · Reply

jimbecker May. 8 at 2:30 PM

$BDTX Jun18 $2.50C Someone bought $628K worth yesterday.

0 · Reply

Ramanda87 May. 7 at 5:38 PM

$BDTX running out of patience with this one

0 · Reply

Marklacey123 May. 7 at 3:07 PM

$BDTX PIPER SANDLER OVERWEIGHT PRICE TARGET $8

3 · Reply

Marklacey123 May. 7 at 1:42 PM

$BDTX -8% is a bit oversold on results that beat consensus and patient 1st dosing……just my view

0 · Reply

Stock_Squatch_Watcher May. 7 at 1:26 PM

$BDTX Interesting they did not PR first patient dosing (which occurred within the last 6 days) for the brain study. Looking forward to ASCO data and of course still hoping for P3 lung partner. 🫈

0 · Reply

focafoca99 May. 7 at 11:43 AM

$BDTX released its Q1 2026 financial results for the quarter ended March 31, 2026.

0 · Reply

Marklacey123 May. 7 at 11:35 AM

$BDTX Numbers beat consensus

0 · Reply

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-04-29T10:21:57.000Z - 14 days ago

Black Diamond price target raised to $11 from $10 at H.C. Wainwright

Apr 21, 2026, 10:40 AM EDT - 21 days ago

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

2026-03-17T11:51:25.000Z - 2 months ago

Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

2026-03-16T20:05:26.000Z - 2 months ago

Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)

Mar 16, 2026, 4:01 PM EDT - 2 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 4, 2026, 1:10 PM EST - 2 months ago

Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:01 PM EST - 2 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

2026-01-16T11:55:20.000Z - 4 months ago

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

Dec 4, 2025, 1:00 PM EST - 5 months ago

Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T17:40:19.000Z - 5 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

2025-12-03T17:35:12.000Z - 5 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

Dec 3, 2025, 8:00 AM EST - 5 months ago

Black Diamond Therapeutics Transcript: Study Update

2025-12-03T12:11:22.000Z - 5 months ago

Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib

Dec 3, 2025, 7:01 AM EST - 5 months ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 5 months ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

2025-11-17T21:50:17.000Z - 6 months ago

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

2025-11-13T22:25:31.000Z - 6 months ago

Black Diamond Therapeutics files $500M mixed securities shelf

Nov 12, 2025, 9:00 AM EST - 6 months ago

Black Diamond Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:20 AM EST - 6 months ago

Black Diamond Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-06T12:35:52.000Z - 6 months ago

Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

2025-11-06T12:35:40.000Z - 6 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Nov 6, 2025, 7:30 AM EST - 6 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-10-15T20:36:00.000Z - 7 months ago

Black Diamond Therapeutics resumed with a Buy at Stifel

2025-09-30T16:30:10.000Z - 8 months ago

Black Diamond Therapeutics initiated with a Buy at Freedom Capital

2025-09-04T09:25:07.000Z - 8 months ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-09-03T20:15:10.000Z - 8 months ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-08-11T10:21:34.000Z - 9 months ago

Black Diamond price target lowered to $10 from $12 at H.C. Wainwright

2025-08-07T11:42:25.000Z - 9 months ago

Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)

2025-08-07T11:42:19.000Z - 9 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Aug 7, 2025, 7:30 AM EDT - 9 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-07-01T10:51:03.000Z - 11 months ago

Black Diamond Therapeutics resumed with an Outperform at Raymond James

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 8, 2025, 1:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 6, 2025, 4:01 PM EST - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 4, 2024, 3:00 PM EST - 1 year ago

Black Diamond Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 9:45 AM EST - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Study Update

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 1, 2024, 10:00 AM EDT - 2 years ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 2 years ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 29, 2023, 8:57 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 4:23 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 17, 2023, 4:01 PM EDT - 3 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

Mar 9, 2023, 7:30 AM EST - 3 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Jan 5, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

Nov 8, 2022, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 9, 2022, 8:00 AM EDT - 4 years ago

Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 3, 2022, 8:00 AM EDT - 4 years ago

Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

mdemattia May. 10 at 1:04 AM

$BDTX Lot of action in BDTX on Friday. My belief it is pre-ASOC accumulation . 🤞

2 · Reply

jimbecker May. 8 at 5:36 PM

$BDTX Starting small. In @ $3.02.

0 · Reply

Invest2live May. 8 at 3:40 PM

$RXT 1104% in 3 months; congrats 😊🌿🔆 Checkout $ARAY and $AKBA as well as $BDTX

0 · Reply

jimbecker May. 8 at 2:30 PM

$BDTX Jun18 $2.50C Someone bought $628K worth yesterday.

0 · Reply

Ramanda87 May. 7 at 5:38 PM

$BDTX running out of patience with this one

0 · Reply

Marklacey123 May. 7 at 3:07 PM

$BDTX PIPER SANDLER OVERWEIGHT PRICE TARGET $8

3 · Reply

Marklacey123 May. 7 at 1:42 PM

$BDTX -8% is a bit oversold on results that beat consensus and patient 1st dosing……just my view

0 · Reply

Stock_Squatch_Watcher May. 7 at 1:26 PM

$BDTX Interesting they did not PR first patient dosing (which occurred within the last 6 days) for the brain study. Looking forward to ASCO data and of course still hoping for P3 lung partner. 🫈

0 · Reply

focafoca99 May. 7 at 11:43 AM

$BDTX released its Q1 2026 financial results for the quarter ended March 31, 2026.

0 · Reply

Marklacey123 May. 7 at 11:35 AM

$BDTX Numbers beat consensus

0 · Reply

justiceforb_85 May. 3 at 12:13 AM

$BDTX this presentation ("Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations") will be key to the company's valuation, especially if we see activity in C797S mutations.

0 · Reply

justiceforb_85 May. 2 at 4:06 AM

$BDTX look forward to the silevertinib update. Question is whether it will be a niche drug for the C797S space? Otherwise so much competition in other non-classical mutations.

0 · Reply

Orlandotrader May. 1 at 7:29 PM

$BDTX Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. Presentations May 30,31, June 2.

0 · Reply

Orlandotrader May. 1 at 7:25 PM

$BDTX Early CNS performance is the company’s most tangible differentiator so far. In first-line NSCLC patients with non-classical EGFR mutations, silevertinib produced a 60% objective response rate and an 86% CNS response rate, with no new safety concerns observed at the time of the update If durability metrics develop favorably, that kind of intracranial activity can support clinical positioning in patients at high risk for brain metastases, where prescribers often weigh CNS control heavily. The planned progression-free survival update in the second quarter of 2026 is therefore a pivotal readout for how far this signal can translate into a more durable benefit profile.

1 · Reply

Marklacey123 Apr. 29 at 11:28 AM

$BDTX Today...........H.C. Wainwright analyst Robert Burns raised the firm's price target on Black Diamond Therapeutics to $11 from $10 and keeps a Buy rating also BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11

1 · Reply

DARKP00L Apr. 29 at 10:51 AM

$BDTX 06:38 on Apr. 29 2026 BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11 #tradeideas

0 · Reply

chole1 Apr. 28 at 2:37 PM

$BDTX so the longer we need the wait the better the pfs data will be? any guesses where the pfs cld end up?

1 · Reply

Stock_Squatch_Watcher Apr. 24 at 1:19 PM

$BDTX Market casualty yesterday. Let’s see how this responds today. ✌️🫈

1 · Reply

Invest2live Apr. 23 at 6:37 PM

$ON 91% already; congrats 🌿🎈🌿 Checkout $AKBA and $MSFT as well as $BDTX

0 · Reply

lovestockstwits Apr. 22 at 3:59 PM

$BDTX seriously when was the last time this was red ..

2 · Reply

pzthk6 Apr. 22 at 2:25 PM

$BDTX Still on a great run for the past month (not quite CAR, but a very solid stair step).

0 · Reply

Marklacey123 Apr. 22 at 2:05 PM

$BDTX Co. is speaking at Jefferies today - On Wed, April 22, @12PM ET, we will host a virtual fireside w/ BDTX management -- Mark Velleca (CEO), Liz Buck (CSO) and Erika Jones (SVP,Finance). Clin update is on track for 2Q26 (likely @ASCO; titles post 4/21), w/preliminary DOR and PFS data from the ph.II trial of silevertinib in patients w/ non-classical EGFR-mutant NSCLC in the 1L setting. BDTX also plans to start a randomized ph.II trial of silevertinib in newly diagnosed EGFR-altered GBM in 2Q26.

0 · Reply

Market Cap	168.47M
Revenue (ttm)	70.00M
Net Income (ttm)	22.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	31.96%
Debt to Equity Ratio	0.00

Volume	662,400
Avg Vol	796,228
Day's Range	N/A - N/A
Shares Out	57.30M
Stochastic %K	53%
Beta	3.34
Analysts	Strong Sell
Price Target	$9.86